AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
AL amyloidosis (light chain amyloidosis) was a chemotherapy-and-stem-cell-transplant category. Daratumumab plus cyclophosphamide-bortezomib-dexamethasone is now first-line standard of care after the ANDROMEDA trial, isatuximab plus VRd combinations are reading out, and emerging anti-amyloid antibody programs (birtamimab, others) are in late-stage trials targeting amyloid clearance from organs. The cardiac amyloidosis diagnostic-pathway integration (covered in earlier rounds for ATTR-CM) extends to AL amyloidosis identification.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.